The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years. Yorkville agreed to ...
Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...
RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double ...
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the “Company”, an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is ...